Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 23354471)

1.

FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.

Quinn MC, Wojnarowicz PM, Pickett A, Provencher DM, Mes-Masson AM, Davis EC, Tonin PN.

Int J Oncol. 2013 Mar;42(3):912-20. doi: 10.3892/ijo.2013.1797. Epub 2013 Jan 23.

PMID:
23354471
2.

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.

Gambaro K, Quinn MC, Cáceres-Gorriti KY, Shapiro RS, Provencher D, Rahimi K, Mes-Masson AM, Tonin PN.

BMC Cancer. 2015 Mar 17;15:135. doi: 10.1186/s12885-015-1138-8.

3.

Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.

Henriksen R, Sørensen FB, Ørntoft TF, Birkenkamp-Demtroder K.

Tumour Biol. 2011 Aug;32(4):671-6. doi: 10.1007/s13277-011-0167-4. Epub 2011 Mar 12.

PMID:
21399973
4.

Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.

Wojnarowicz PM, Provencher DM, Mes-Masson AM, Tonin PN.

Int J Oncol. 2012 Jun;40(6):1865-80. doi: 10.3892/ijo.2012.1371. Epub 2012 Feb 14.

PMID:
22344671
5.

VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN.

Mol Oncol. 2013 Jun;7(3):513-30. doi: 10.1016/j.molonc.2012.12.006. Epub 2013 Jan 16.

6.

The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN.

PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20.

7.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
8.

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J; Australian Ovarian Cancer Study Group, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju149. doi: 10.1093/jnci/dju149. Print 2014 Jul.

PMID:
24957074
9.

Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.

Darb-Esfahani S, Fritzsche F, Kristiansen G, Weichert W, Sehouli J, Braicu I, Dietel M, Denkert C.

Virchows Arch. 2012 Aug;461(2):109-16. doi: 10.1007/s00428-012-1273-4. Epub 2012 Jul 3.

PMID:
22752467
10.

TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IeM.

J Pathol. 2012 Feb;226(3):421-6. doi: 10.1002/path.3023. Epub 2011 Dec 23.

PMID:
21990067
11.

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK.

Mod Pathol. 2009 Sep;22(9):1243-50. doi: 10.1038/modpathol.2009.92. Epub 2009 Jun 12.

12.

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Wojnarowicz P, Gambaro K, de Ladurantaye M, Quinn MC, Provencher D, Mes-Masson AM, Tonin PN.

Oncogenesis. 2012 Sep 10;1:e27. doi: 10.1038/oncsis.2012.25.

13.

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.

Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.

Clin Cancer Res. 2004 Aug 1;10(15):5168-77.

14.

Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A.

Neoplasia. 2011 Oct;13(10):899-911.

15.

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

Köbel M, Reuss A, Bois Ad, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB.

J Pathol. 2010 Oct;222(2):191-8. doi: 10.1002/path.2744.

PMID:
20629008
16.

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH.

Clin Cancer Res. 2005 Sep 1;11(17):6116-26.

17.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM.

J Pathol. 2010 Feb;220(3):392-400. doi: 10.1002/path.2659.

PMID:
19967725
18.

The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Kuhn E, Kurman RJ, Soslow RA, Han G, Sehdev AS, Morin PJ, Wang TL, Shih IeM.

Am J Surg Pathol. 2012 Dec;36(12):1826-34. doi: 10.1097/PAS.0b013e31825ec07a.

19.

[Expression and promotor methylation of p73 gene in ovarian epithelial tumors].

Zhang YL, Guo XR, Shen DH, Cheng YX, Liang XD, Chen YX, Wang Y.

Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):33-8. Chinese.

PMID:
22455848
20.

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D.

Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk